It’s a joke to call these guidelines “consensus of international experts” when there not even a pretense to go beyond Europe and North America Just be honest folks Call it your own consensus 🤷🏻‍♂️

#Nifty BULLS heading into the weekend.

Happy to share our experience... What immunotherapy can achieve in advanced non metastatic HNSCC ? hope this will help our patients in india.. 🇮🇳 @ICMRDELHI @csoncol

Delighted to see this impactful study from CMC Vellore @OffCMCVellore on low-dose immunotherapy in advanced head and neck cancer gaining broader recognition! Congratulations to @jtgeorgy, @todrashish, @ajoyojohn and the team back home! https://t.co/DId2WMlaM3

amazing effort Dr @SirohiBhawna .. your work in needy areas of the country inspires so many of us who are privileged to be mentored by you..

Bloomberg @business (Global, NY) @RobertLangreth recently featured our work from @OffCMCVellore Medical Oncology & Haematology and @TataMemorial: low-dose immunotherapy and potential for equitable cancer care. What if 1/6th the dose works just as well? https://t.co/CYAuvUz609

Pleased to share our work featuring in this Bloomberg story.. @csoncol @VPrasadMDMPH @oncology_bg @OffCMCVellore https://t.co/rdGyRtkGQE 🎥 Video Segment: https://t.co/D6thoHi95t 🔍

🙏 Grateful to @DeptHealthRes @ICMRDELHI for DIAMOnDS ( https://t.co/ExckNs8jbO)- zonal molecular oncopathology labs, offering free-of-cost advanced molecular diagnostics, expanding equitable access nationwide. Our Pathology Dept @OffCMCVellore is part of this initiative.

📢Our new paper @OffCMCVellore Pathology, MedOnc out in @ecancer https://t.co/Tv8wcQScOh After Dr. @ullas_batra's report, this is largest Indian series of tepotinib-Rxed METex14 mNSCLC. Led by @todrashish, Dr. Rekha Pai @ajoel_84, Dr. Rohini @ajoyojohn Dr. Deepa Susan #LCSM

Phaeochromocytomas and Paragangliomas are rare neuroendocrine tumors arising from the chromaffin cells..But malignant versions are even rarer..Glad to be part of one of the largest Indian series on this in recent times..Published today. https://t.co/Gkd48Z7kgc @IndiaESI

amazing, TMCi should be a standard treatment in every suitable patient..not only in LMIC ..

https://t.co/vErR1fmMkU Our experience in very advanced LAHNSCC .. there is probably a role of intensified local treatment in exceptional responders..we need prospective randomised trials @TataMemorial @CancerGridIndia @VanitaNoronha @sarbani30 @drmpk91 @jtgeorgy @CancerCare

💸 Why Financial Toxicity (#FinTox) matters in cancer care Key insights from Dr @fumikochino’s excellent plenary at #MASCC25 : 🔻 It erodes quality of life and social functioning 📉 Leads to borrowing, reduced spending on basics and leisure; the burden worsens over time 💥

Congrats @drmpk91 for presenting your Mind & Money study from our medonc dept @OffCMCVellore as oral at #MASCC25! these are major barriers to cancer care and this study is crucial progress toward equitable care. @ajoel_84 @ajoyojohn @Harikri44884728 @sanujthomas

Congratulations @drmpk91 for your eye opening work! Financial distress is a known problem for Indian cancer patients, but it is rarely measured or accounted for in practice or studies. Integrated targeted referrals improving multi- domain distress is encouraging!

🎙️ Proud to present our work from Med Onc @OffCMCVellore at #MASCC25 Interim results of “MIND & MONEY” 💭💰 Mentors: @todrashish @JeniferJeba @askdheeraj Can we ⬇️ distress & #FinancialToxicity in pts with Stage IV cancer through structured screening + targeted referrals? 🧵👇

PRAGRAD, a new patient-driven treatment approach for very advanced oral cavity #cancers (which cannot be surgically removed) shows significant improvement in patient outcomes: prospective study by CMC #research team. Instead of a one-size-fits-all plan, #patients are given the

🧪 Unresectable Oral Cavity Cancer: Radical Rx Feasible? This observational study shows that patient choice-driven radical treatment (URAD) in unresectable OCC led to: ✅ Better QoL (pain score ↑ from 26 ➡️ 80) ✅ Improved survival (RRAD OS: 37.9 mo vs UPA: 6.0 mo) 📊 77%

🧬 The Liquid Biopsy Truth: What $40 Billion in Cancer Screening Really Buys Us A masterful @NewYorker investigation by @DrSidMukherjee reveals why finding cancer early isn't what we think it is. Here's what longevity clinics don't tell you... 🧵

**PRAGRAD: A New Approach to Treating Very Advanced Oral Cancer** latest from our group @cmcvelloreoff @CancerCareMASCC @oncoalert @ASCOPost @myESMO @LizzySmyth1 https://t.co/1uyBO4ZsBU